Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes

Journal of Diabetes

Volumn 9, Issue 5, 2017, Pages 502-509

  Cao, Ying ^a   Gao, Fang ^a   Zhang, Qian ^a   Xu, Lingling ^a   Wan, Qian ^a   Li, Wenqi ^a   Li, Jimin ^a   Wang, Ling ^a   Xue, Yaoming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

dipeptidyl peptidase 4 inhibitor; insulin; sitagliptin; type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DIET RESTRICTION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; WEIGHT CHANGE; ANALYSIS; BLOOD; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; MALE; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 84988666413     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12436     Document Type: Article

References (20)

1. Ji L, Lu J, Guo X, Yang W, Weng J, Jia W. Status of blood glucose control and treatment of type 2 diabetes in China. Chin J Diabetes Mellit. 2012; 4: 397–401 (in Chinese).
2. American Diabetes Association (ADA). 7. Approaches to glycemic treatment. Diabetes Care. 2015; 38(Suppl. 1): S41–S48.
3. Aschner P, Sethi B, Gomez-Peralta F et al. Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: The open-label, randomized GALAPAGOS study. J Diabetes Complications. 2015; 29: 838–845.
4. Kadowaki T, Tajima N, Odawara M et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013; 4: 160–172.
5. Vilsbøll T, Rosenstock J, Yki-Järvinen H et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010; 12: 167–177.
6. Charbonnel B, Schweizer A, Dejager S. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: What is the evidence? Hosp Pract. 2013; 41: 93–107.
7. Hong E, Khang A, Yoon J et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012; 14: 795–802.
8. Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: A systematic review. Curr Med Res Opin. 2014; 30: 431–445.
9. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvement of Glycemic control in subjects with poorly controlled type 2 diabetes. Diabetes Care. 2005; 28: 1282–1288.
10. Lv X, Li Q, Jia W et al. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study. Curr Med Res Opin. 2012; 28: 533–541.
11. Tibaldi J. Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus. Am J Med Sci. 2014; 347: 491–501.
12. Rizos CE, Ntzani EE, Papanas N et al. Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: A systematic review. Curr Vasc Pharmacol. 2013; 11: 992–1000.
13. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87: 1239–1246.
14. Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin. Clin Pharmacol Ther. 2007; 81: 761–767.
15. Shimoda S, Iwashita S, Ichimori S et al. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocr J. 2013; 60: 1207–1214.
16. Zhou J, Zheng F, Guo X et al. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. Diabetes Metab Res Rev. 2015; 31: 725–733.
17. Lankisch MR, Del Prato S, Dain MP, Mullins P, Owens DR. Use of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials. Prim Care Diabetes. 2016; 10: 51–59.
18. Bergman AJ, Stevens C, Zhou Y et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006; 28: 55–72.
19. Ahluwalia R, Vora J. Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Ther. 2011; 2: 146–161.
20. Vora J. Combining incretin-based therapies with insulin: Realizing the potential in type 2 diabetes. Diabetes Care. 2013; 36(Suppl. 2): S226–S232.